Transcode Therapeutics completes Cohort 3 dosing in Phase 1 trial of TTX-MC138

TransCode Therapeutics (RNAZ) announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit the emergence and progression of many metastatic cancers. The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its review of Cohort 1 and 2 safety and pharmacokinetic data and is monitoring Cohort 3 as preliminary data becomes available. The dose administered to patients in the third cohort is approximately double the dose administered in the second cohort. No significant safety or dose limiting toxicities have been reported in any of the trial’s nine patients. To date, the analyses suggest that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from TransCode’s previous Phase 0 clinical trial. TTX-MC138 activity increased with the escalated dose administered in Cohort 2 and was consistent at subsequent administrations suggesting a favorable pharmacokinetic profile.